Aim: The use of sodium glucose co-transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) has been limited, primarily because glycaemic efficacy is dependent on kidney function. We performed a systematic review and metaanalysis to assess the efficacy and safety of SGLT2 inhibitors in patients with T2DM and CKD, defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 . 
| INTRODUCTION
Sodium glucose co-transporter 2 (SGLT2) inhibitors are approved for use in type 2 diabetes mellitus (T2DM) and act by blocking glucose and sodium re-uptake in the proximal renal tubule, thereby promoting glycosuria. 1 In addition, SGLT2 inhibitors enhance natriuresis, cause intravascular volume contraction and alter intra-renal haemodynamics, which probably contribute to beneficial effects on blood pressure, body weight and albuminuria. 1 These pleiotropic effects have translated into reductions in cardiovascular events and preservation of kidney function in large cardiovascular outcome trials [2] [3] [4] [5] [6] and, as a consequence, this class of agent is now recommended as second-line therapy after metformin for individuals with T2DM and established cardiovascular disease in the latest North American and European clinical practice guidelines. [7] [8] [9] [10] Because of their renal-based mechanism of action, and the potential that the balance of benefits and risks may differ among individuals with chronic kidney disease (CKD), SGLT2 inhibitors are currently not approved for use in individuals with an estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m 2 for empagliflozin and canagliflozin, and <60 mL/min/1.73 m 2 for dapagliflozin and ertugliflozin. 11, 12 The glucose-lowering effect of SGLT2 inhibitors depends on glomerular filtration and is progressively attenuated as kidney function declines. 13, 14 In contrast, other non-glycaemic effects, such as reductions in blood pressure and albuminuria, appear similar across different levels of kidney function, [13] [14] [15] raising questions about the effects on cardiovascular, renal and safety outcomes in indviduals with reduced eGFR.
Approximately 40% of individuals with T2DM develop CKD during their lifetime, 16, 17 representing one of the highest risk groups for cardiovascular complications and progression to end-stage kidney disease. 18 Because of this, it is important to understand whether the benefits of SGLT2 inhibition might extend to those with T2DM and CKD, and whether the risk of adverse events, in particular renal safety, are similar or different for individuals with CKD.
Previous meta-analyses have assessed the effects of SGLT2 inhibition in individuals with reduced kidney function. [19] [20] [21] These studies largely focused on intermediate markers of efficacy such as glycated haemoglobin (HbA1c), body weight and albuminuria, and most did not quantitatively synthesize the three large cardiovascular outcome trials published to date. In addition, these studies did not report on specific safety outcomes of interest in patients with CKD, such as fractures, amputations and diabetic ketoacidosis.
We, therefore, undertook a systematic review and meta-analysis of randomized controlled trials to better understand the role of this class of agent for cardio-renal protection in individuals with T2DM
and CKD, defined as eGFR <60 mL/min/1.73 m 2 .
| METHODS
This study is a systematic review and meta-analysis assessing the class and individual drug effects of SGLT2 inhibitors as compared to placebo or active control in individuals with T2DM and CKD. It was conducted and reported in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. 22 
| Data sources and searches
We searched the following data sources until 7 August 2018 to identify relevant randomized controlled trials: MEDLINE via Ovid (from 1 January 1946), EMBASE (from 1 January 1947) and the Cochrane Central Register of Controlled Trials (without date restriction). The text words and medical subject headings comprised terms relating to "sodium-glucose transporter 2," "clinical trial" and the individual drug names (Supporting Information Table S1 ). The search was limited to data from randomized controlled trials, without language restriction.
We also searched websites of the US Food and Drug Administration, 
| Study selection
We included all studies or regulatory documents that reported individual randomized controlled trial data on any SGLT2 inhibitor vs placebo or active control in adult humans with T2DM when studies reported data for participants with CKD, defined as eGFR <60 mL/min/1.73 m 2 . Individual trial data were supplemented or substituted, outcome by outcome, with information from pooled analyses when the pooled analyses provided more data and were clearly identified as not overlapping with another report. Duplicate reports and those not reporting outcomes of interest were excluded. We did not exclude studies based on length of follow-up. Where there were multiple reports of a single study, the report with the longest follow-up period was included, and if different reports of the same trial provided data for different outcomes, the complete non-overlapping data were extracted from each report. In cases where two or more studies provided data for a relevant outcome with similar numbers of participants, we included the study with the largest number of total patientyears.
| Data extraction and quality assessment
Two authors (B. L. N. and T. T.) independently extracted all data using a standardized electronic spreadsheet. Attempts were made to contact individual study authors or study sponsors wherever possible for additional data, to supplement or substitute for published reports if responses to these contacts provided more comprehensive or complete data. , the eGFR subgroups were merged using the methods described below to obtain a best estimate for the eGFR <60 mL/min/1.73 m 2 group.
To synthesize the effect of SGLT2 inhibitors on biomarkers, we calculated the differences in treatment effect and standard error from data provided in each study, pooled by the generic inverse variance method with a random-effects model. We calculated the effects of For cardiovascular, renal and safety outcomes, we sought to use, in order of preference, hazard ratios and 95% confidence intervals, or the incidence rate ratio and 95% confidence interval (based upon events/participant years), or the risk ratio (based upon events/participant numbers). This approach was used to optimize our ability to accurately detect treatment effects of SGLT2 inhibitors, particularly for canagliflozin, where the integrated analysis and reporting of two parallel companion trials, CANVAS and CANVAS-R, with different lengths of follow-up precluded use of risk ratios. 24 If required, hazard ratio estimates combining two or more subgroups (eg, male and female genital infections) were merged, using the fixed effects model.
When calculating risk ratios in studies comparing different SGLT2
inhibitor doses, the number of events and participants were combined across active treatment arms and compared to control to obtain an estimate for SGLT2 inhibitor vs placebo or active control.
The same was done when data were provided for eGFR subgroups but not for individuals with CKD overall. Wherever possible, triallevel data were used. To ensure maximum use of available data, when an outcome was reported in both individual trials and pooled analyses, we included summary estimates and uncertainty intervals only when these included more data than could be obtained from individual trials, ensuring no overlap in included participants. As was the case with continuous outcomes, image extraction software was used to retrieve data presented in figures without corresponding numerical data.
Risk ratios expressed as relative risks (RR), which were obtained using a random effects model, were used as the summary measure of association across studies. As the outcomes evaluated could be considered rare outcomes, reported hazards, rate and risk ratios were assumed to approximate the same measure of relative risk following Cornfield's rare disease outcome assumption. 25 The percentage of variability across pooled estimates attributable to heterogeneity beyond chance was estimated using the I 2 statistic and also by calculating the P value for heterogeneity. I 2 statistics of 0-25%, 26-75%, and 76-100% were considered to reflect a low, moderate, and high likelihood of differences beyond chance, respectively. A P value for heterogeneity of <0.05 was also considered to probably reflect a high likelihood of differences beyond chance. Statistical analyses were performed using R Version 3.4.4 (R Foundation for Statistical Computing, Vienna, Austria) with the package "meta" Version 4.9-1 as a statistical software.
| RESULTS
The literature search yielded 2557 articles, of which 734 were reviewed in full text (Figure 1) . One large cardiovascular outcome trial for dapagliflozin was identified after the systematic literature search. 6 In total, 27 studies yeilded data on biomarkers or on cardiovascular, 47 ( Figure 1 and Supporting Information Table S2 ). The eight pooled analyses and one regulatory report combined data from 41 individual trials from which results were not individually available for the CKD population. Thus, in total, data from 59 trials contributed data to the meta-analysis: 18 studies from which individual trial data were available for the CKD population, as well as 41 trials which were Information Table S3 ). Of the 59 trials from which data were used for this analysis, Figure S1 ). Tests for publication bias were not performed because of the small number of studies reporting the effect of SGLT2 inhibitors on the main composite of cardiovascular and renal outcomes, as well as all-cause mortality. Results for effects on biomarkers and on cardiovascular, renal and safety outcomes by individual study are also presented online (Supporting Information Figures S3-S6 ).
| Biomarker outcomes
Data on a range of biomarkers were available for up to seven SGLT2 inhibitors across four to 14 studies. Overall, SGLT2 inhibitors reduced HbA1c, fasting glucose, systolic and diastolic blood pressure and body weight, with no significant effect on serum potassium (Figure 1 ). These agents also reduced albuminuria, whether reported as percentage or absolute change ( Figure 1 and Supporting Information Figure S2 , respectively). There was significant evidence of heterogeneity across SGLT2 inhibitors for the effect on HbA1c
(I 2 = 65%; P-heterogeneity <0.01), moderate evidence of heterogeneity for fasting glucose (I 2 = 52%; P-heterogeneity = 0.05), but no evidence of heterogeneity of effects for the other biomarkers (all I 2 ≤ 12%; all P-heterogeneity ≥0.34) (Figure 2 ). The difference in the effect on HbA1c across individual agents was substantively attenuated by excluding the tofogliflozin study (I 2 = 39%; P-heterogeneity = 0.15) in which a particularly large reduction in HbA1c was observed.
The effect of SGLT2 inhibitors on HbA1c was consistent in analyses stratified by the duration of follow up (≥26 vs <26 weeks; I 2 = 0%; P-heterogeneity = 0.50). We conducted sensitivity analyses comparing data from the three cardiovascular outcome trials with that from other SGLT2 inhibitor trials. There was no clear evidence of heterogeneity between the two trial categories for any of the cardiovascular outcomes (all I 2 < 50%; all P-heterogeneity >0.15). Exclusion of non-cardiovascular outcome trial data did not materially change overall effect estimates for most cardiovascular outcomes. For myocardial infarction, the treatment effect became non-significant when analysing data from only the three cardiovascular outcome trials (RR, 0.81; 95% CI, 0.62-1.07). 
| Cardiovascular outcomes

| Renal outcomes
| Safety outcomes
The risks of adverse outcomes with SGLT2 inhibitors are displayed in all P-heterogeneity ≤0.04). In each case, empagliflozin was associated with a lesser risk compared to the other agents ( Figure 5 ). SGLT2
inhibitors did not increase the risk of renal-related adverse events, acute kidney injury or hyperkalaemia (Figure 4) . This class of agent exerts multiple beneficial metabolic effects, that is, lowering HbA1c, blood pressure and body weight, that might contribute to cardiovascular risk reduction. However, the reduction in HbA1c for individuals with CKD was modest in comparison to that previously reported for the general T2DM population. 2, 3, 89 This was consistent with the known mechanism of action of these agents, for which glycaemic efficacy is proportional to filtered glucose load. 1 The observed heterogeneity of the effect on HbA1c and fasting glucose across SGLT2 inhibitors may be related to differences in mean baseline HbA1c or kidney function across included trials. Alternatively, observed differences in glycaemic efficacy may be related to bias in the statistical methods used to handle missing repeated measurements across the contributing studies; some of these approaches have been shown to be particularly problematic, including in the context of trials concerning SGLT2 inhibitors. 90 Nevertheless, given only small and variable improvements in HbA1c, as well as the inconsistent evidence of glucose lowering in the prevention of macrovascular complications in T2DM, 91, 92 these results suggest that improved glycaemic control is not driving the observed reduction in cardiovascular events in this population.
Augmented natriuresis and intravascular volume contraction, the putative mechanisms for blood pressure-lowering with this class of agents, 1 would also be anticipated to be attenuated in CKD, but there appears to be no corresponding attenuation of the antihypertensive effect. It might be that individuals with CKD are more sensitive to small changes in renal salt handling and changes in FIGURE 4 Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in individuals with type 2 diabetes and chronic kidney disease (estimated glomerular filtration rate < 60 mL/min/1.73 m 2 ). Abbreviations: CI, confidence interval; ESKD, end-stage kidney disease; HR, hazard ratio; n, number of cases with events; N, group size; RR, risk ratio. a, Week 6 (CANVAS) or 13 (CANVAS-R) to last available measurement was used. b, Week 4 to the last value on treatment was used. c, For the DECLARE-TIMI 58 trial, 40% decrease in eGFR was substituted for doubling of serum creatinine in the renal composite outcome intravascular volume, 93, 94 or that haemodynamic effects may be enhanced by concurrent use of diuretic therapies, 95 which were more prevalent in individuals with CKD in two large included trials. 15, 96 Regardless of the explanation, the preserved effects on natriuresis and blood pressure implicate sodium retention and intravascular volume expansion as a key pathway to cardiovascular complications, especially heart failure. 97 Resulting reductions in cardiac preload and afterload with SGLT2 inhibitors are likely to be particularly beneficial in diabetic kidney disease, which is characterized by glomerular and systemic haemodynamic dysregulation that in turn contributes to higher rates of subclinical or overt cardiac dysfunction in this population. 98 Other direct cellular and metabolic effects might also play a role. 99 SGLT2 inhibitors shift metabolism from carbohydrates towards lipolysis, thus promoting mild ketogenesis, which may provide an alternative energy substrate to myocardial cells in the setting of ischaemic stress.
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FIGURE 5 Effects of SGLT2 inhibitors on safety outcomes in individuals with type 2 diabetes and chronic kidney disease (estimated glomerular filtration rate < 60 mL/min/1.73 m 2 ). Abbreviations: HR, hazard ratio; n, number of cases with events; N, group size; NA, not available; RR, risk ratio A key physiological concept underpinning the probable renoprotective effect of this class of agents is that they reduce hyperfiltration, a critical process in the pathogenesis of diabetic kidney disease. provide important data on potential renal benefits in both populations. 106, 107 In conclusion, currently available data suggest that SGLT2 inhibitors reduce the risk of cardiovascular and renal outcomes in patients with T2DM and CKD, without clear evidence of additional safety concerns; however, the robustness of these findings requires confirmation in upcoming dedicated CKD outcome trials. 
